+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Infectious Diseases Drugs Market Research Reports

Antimalarial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2030 - (By Drug Class Coverage, Route of Administration Coverage, Distribution Channel Coverage, Geographic Coverage and Leading Companies) - Product Thumbnail Image

Antimalarial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2030 - (By Drug Class Coverage, Route of Administration Coverage, Distribution Channel Coverage, Geographic Coverage and Leading Companies)

  • Report
  • October 2023
  • 185 Pages
  • Global
Antifungal Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030 - By Product, Technology, Grade, Application, End-user and Region (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Thumbnail Image

Antifungal Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030 - By Product, Technology, Grade, Application, End-user and Region (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • July 2023
  • 220 Pages
  • Global
2024 Certain Infectious and Parasitic Diseases Global Market Size & Growth Report with Updated Recession Risk Impact - Product Thumbnail Image

2024 Certain Infectious and Parasitic Diseases Global Market Size & Growth Report with Updated Recession Risk Impact

  • Report
  • October 2024
  • 45 Pages
  • Global
From
Hepatitis D Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Hepatitis D Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • July 2022
  • 71 Pages
  • Global
From
Hepatitis A Virus Cellular Receptor 2 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Hepatitis A Virus Cellular Receptor 2 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 64 Pages
  • Global
From
Respiratory Syncytial Virus Fusion Protein Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Respiratory Syncytial Virus Fusion Protein Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 84 Pages
  • Global
From
Hepatitis B Virus Surface Antigen Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Hepatitis B Virus Surface Antigen Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 72 Pages
  • Global
From
Viral Conjunctivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Viral Conjunctivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • April 2022
  • 40 Pages
  • Global
From
Genital Herpes Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Genital Herpes Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • April 2022
  • 86 Pages
  • Global
From
Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H2 2020 - Product Thumbnail Image

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 65 Pages
  • Global
From
Glycoprotein 41 (gp41) - Pipeline Review, H2 2020 - Product Thumbnail Image

Glycoprotein 41 (gp41) - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 65 Pages
  • Global
From
Resistant Pseudomonas aeruginosa Infections - Pipeline Review, H2 2020 - Product Thumbnail Image

Resistant Pseudomonas aeruginosa Infections - Pipeline Review, H2 2020

  • Drug Pipelines
  • September 2020
  • 57 Pages
  • Global
From
Genital Herpes - Pipeline Review, H2 2020 - Product Thumbnail Image

Genital Herpes - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 123 Pages
  • Global
From
Bacterial Vaginosis - Pipeline Review, H2 2020 - Product Thumbnail Image

Bacterial Vaginosis - Pipeline Review, H2 2020

  • Drug Pipelines
  • July 2020
  • 75 Pages
  • Global
From
Toxoplasmosis - Pipeline Review, H1 2020 - Product Thumbnail Image

Toxoplasmosis - Pipeline Review, H1 2020

  • Drug Pipelines
  • June 2020
  • 48 Pages
  • Global
From
COVID-19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update - Product Thumbnail Image

COVID-19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update

  • Report
  • December 2022
  • 116 Pages
  • Global
From
Mycobacterium Tuberculosis Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update - Product Thumbnail Image

Mycobacterium Tuberculosis Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update

  • Report
  • October 2022
  • 115 Pages
  • Global
From
Human Immunodeficiency Virus (HIV) Point of Care (POC) Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update - Product Thumbnail Image

Human Immunodeficiency Virus (HIV) Point of Care (POC) Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update

  • Report
  • August 2022
  • 95 Pages
  • Global
From
Argentina Tuberculosis Drugs Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2032 - Product Thumbnail Image

Argentina Tuberculosis Drugs Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2032

  • Report
  • May 2024
  • 80 Pages
  • Argentina
From
Brazil Tuberculosis Drugs Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2032 - Product Thumbnail Image

Brazil Tuberculosis Drugs Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2032

  • Report
  • May 2024
  • 80 Pages
  • Brazil
From
Loading Indicator

The Infectious Diseases Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs used to treat infectious diseases. These drugs are used to treat a wide range of illnesses, from common colds to more serious conditions such as HIV/AIDS, malaria, and tuberculosis. The market is highly competitive, with many companies vying for a share of the market. Infectious Diseases Drugs are typically developed through a combination of research and development, clinical trials, and regulatory approval. Companies in the market must also ensure that their products are safe and effective for use in humans. Some of the major players in the Infectious Diseases Drugs market include Pfizer, GlaxoSmithKline, Merck, Sanofi, and Johnson & Johnson. These companies are involved in the development and production of a wide range of drugs used to treat infectious diseases. Show Less Read more